Press coverage about Redhill Biopharma (NASDAQ:RDHL) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Redhill Biopharma earned a coverage optimism score of 0.04 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.1885938232709 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news articles that may have effected Accern’s analysis:

Redhill Biopharma (NASDAQ:RDHL) opened at $4.63 on Friday. Redhill Biopharma has a 1 year low of $4.30 and a 1 year high of $11.99.

RDHL has been the subject of a number of research reports. Roth Capital restated a “buy” rating and set a $27.00 target price on shares of Redhill Biopharma in a research report on Wednesday, October 4th. Zacks Investment Research upgraded shares of Redhill Biopharma from a “sell” rating to a “hold” rating in a research report on Wednesday, September 20th. Seaport Global Securities initiated coverage on shares of Redhill Biopharma in a research report on Friday, October 6th. They set a “buy” rating and a $19.00 target price for the company. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of Redhill Biopharma in a research report on Tuesday, November 21st. Finally, UBS initiated coverage on shares of Redhill Biopharma in a research report on Wednesday, September 13th. They set a “reduce” rating for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $21.10.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/10/redhill-biopharma-rdhl-earning-somewhat-favorable-news-coverage-report-finds.html.

About Redhill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Insider Buying and Selling by Quarter for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Stock Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related stocks with our FREE daily email newsletter.